Skip to main content

 

FEED
From 30,000+ hand-picked sources

Drugmaker Elan Tempts the SEC to Investigate Its Tangled, Undisclosed Deals

Elan (ELN), the barely competent Irish drugmaker , appears to be tempting the SEC to investigate it after dissident investor Ib Sonderby revealed on his Save Elan blog that the company failed to disclose it bought an epilepsy drug, lorazepam , from Amarin (AMRN), another Irish drugmaker, for $700,000. Read More